B.Riley FBR Reaffirms Their Buy Rating on Harrow Health Inc (HROW)

By Carrie Williams

B.Riley FBR analyst Andrew D’silva maintained a Buy rating on Harrow Health Inc (HROWResearch Report) today and set a price target of $12.75. The company’s shares closed last Monday at $5.35.

D’silva noted:

“Last week, we hosted an NDR for Harrow Health (HROW) in the company’s HROW filed an 8-K, announcing it had ceased operations of Park Compounding, its non-ophthalmology-focused 503A pharmacy in California, and terminated its asset purchase agreement with Noice Rx. Recall: In July, HROW agreed to sell substantially all of Park’s non-ophthalmology pharmaceutical compounding business’ assets to Noice. As we mentioned in our last update (see note dated 8/15/19), we did not update our estimates, post HROW’s 2Q19 print: We were waiting for the divestiture of Park Compounding to be finalized. As a result, we are updating our 3Q19 to 2021 estimates to account for HROW’s 2Q19 results/conference call, NDR, and update on Park Compounding.”

According to TipRanks.com, D’silva is a 3-star analyst with an average return of 1.0% and a 38.5% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals Inc, Oramed Pharmaceuticals, and Anixa Biosciences Inc.

Harrow Health Inc has an analyst consensus of Moderate Buy, with a price target consensus of $13.88.

See today’s analyst top recommended stocks >>

The company has a one-year high of $8.99 and a one-year low of $2.22. Currently, Harrow Health Inc has an average volume of 322.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.